fbpx

molecules of the month

ENT-01

oral ⍺-synuclein aggregation inhibitor

completed Ph. IIb for PD + constipation

natural product

Sci. Adv., 16 November 2022

Enterin Inc., Philadelphia, PA

ENT-01 chemical structure oral ⍺-synuclein aggregation inhibitor- Enterin Inc., Philadelphia, PA
3 mins read

An old molecule and an old target come together. Squalamine was originally discovered in 1993 as an antimicrobial from the liver of the dogfish shark. It’s had a long and interesting history, investigated by Magainin/Genaera as a Ph. II antiangiogenic drug candidate for cancer and as a Ph. III opthalmic candidate for macular degeneration. One of the scientists from Magainin, Michael Zasloff, is now the co-founder and CSO of Enterin, a company trying to develop squalamine as an oral, non-systemic drug for Parkinson’s disease. The Parkinson’s disease hypothesis. α-synuclein aggregation is a hallmark of Parkinson’s disease (PD) and other synucleinopathies. α-synuclein aggregates are neurotoxic, but targeting α-synuclein directly is challenging due to its relatively small size (14 kDa), unclear but…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: